Sara Karlovitch is an associate editor with Targeted Oncology. She received a duel degree in Journalism and Government and Politics from the University of Maryland.
Balstilimab With Zalifrelimab Elicits High, Durable Responses in Recurrent/Metastatic Cervical CancerJanuary 13th 2022
In patients with recurrent and/or metastatic cervical cancer, the second-line combination of balstilimab and zalifrelimab may offer meaningful clinical benefit, but further research is needed.
Acalabrutinib Plus Venetoclax and Rituximab Signals Safety, Efficacy in MCLJanuary 11th 2022
In an interview with Targeted Oncology, Michael Wang, MD, a professor in the department of lymphoma and myeloma at MD Anderson Cancer Center, discussed the safety, efficacy, and tolerability of acalabrutinib plus venetoclax and rituximab in mantle cell lymphoma.
Nivolumab/Relatlimab Combo Improves PFS in Advanced MelanomaJanuary 6th 2022
Efficacy was seen with blocking LAG-3 in combination with PD-1 as a therapeutic strategy for patients with melanoma. Additionally, this research establishes LAG-3 as the third immune checkpoint pathway to have proven clinical benefit in this patient population.